



LEERINK Partners 5th Annual Global Healthcare Conference

John F. Crowley, Chairman and Chief Executive Officer


February 10, 2016

Safe Harbor

This presentation will contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus’ candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products, financing plans, and the projected cash position for the Company. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities, and in particular the timing of an NDA submission for migalastat monotherapy, and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company’s cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2014 and Form 10-Q for the quarter ended June 30, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


Amicus 2016 – Looking Back

Amicus Has Greatly Expanded Product Pipeline, Technologies and Geographies



Amicus 2016 – Continuing the Momentum


Significant Milestones in 2016



Amicus Vision

Amicus Therapeutics is a global biotechnology company at the forefront of developing advanced therapies to treat a range of devastating rare and orphan diseases


Rare &
Devastating
Diseases



Potential
First-in-Class
/ Best-in-
Class



Meaningful
benefits for
patients



Key Drivers of Value

3 Novel Product Candidates Each with \$500M to \$1B+ Market Potential

Fabry

- Migalastat Personalized Medicine (Small Molecule)
- MAA Submitted
- CHMP Opinion Anticipated Early 2016
- Prepared for EU Launch*

Epidermolysis Bullosa (EB)

- Phase 3 Novel Topical Cream (SD-101)
- U.S. Breakthrough Therapy Designation
- Rolling NDA
- Phase 3 Data Expected in 2H16

Pompe

- Novel ERT + Chaperone Treatment Paradigm
- Biologics Manufacturing
- Clinical Study Initiated with Data Anticipated in 2016

R&D Engine and Continued Business Development Activity

*Pending Approval

Strong Balance Sheet

Cash Position Provides Runway Under Current Operating Plan into 1H17

Financial Position	December 31, 2015
Current Cash:	\$214M
Current Debt	\$50M
FY16 Net Cash Spend Guidance:	\$135M-\$155M
Cash Runway	Mid-2017
Capitalization	
Shares Outstanding	125,027,034

Thank You